Related references
Note: Only part of the references are listed.KSHV/HHV8-mediated hematologic diseases
Ethel Cesarman et al.
BLOOD (2022)
Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Savanah D. Gisriel et al.
MODERN PATHOLOGY (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio et al.
LEUKEMIA (2022)
HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases
Stefano Fiori et al.
BIOLOGY-BASEL (2021)
Primary effusion lymphoma occurring in the setting of transplanted patients: a systematic review of a rare, life-threatening post-transplantation occurrence
Magda Zanelli et al.
BMC CANCER (2021)
Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia
Daichi Miyagi et al.
CYTOPATHOLOGY (2020)
Immediate Effects of Dasatinib on the Migration and Redistribution of Naive and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients
Beatriz Colom-Fernandez et al.
FRONTIERS IN PHARMACOLOGY (2019)
Primary effusion lymphoma of the pleural space: Report of a rare complication of cardiac transplant with review of the literature
Irfan Ali R. Kugasia et al.
TRANSPLANT INFECTIOUS DISEASE (2019)
Primary effusion lymphoma in a human immunodeficiency virus-negative patient with unexpected unusual complications: a case report
Liliana Fernandez-Trujillo et al.
JOURNAL OF MEDICAL CASE REPORTS (2019)
Dasatinib increases endothelial permeability leading to pleural effusion
Carole Phan et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma
Tomomi Kubota et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
KSHV/HHV8-negative Effusion-based Lymphoma, a Distinct Entity Associated With Fluid Overload States
Serge Alexanian et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma
Lawrence D. Kaplan
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Extracavitary KSHV-associated Large B-Cell Lymphoma A Distinct Entity or a Subtype of Primary Effusion Lymphoma? Study of 9 Cases and Review of an Additional 43 Cases
Zeng-Gang Pan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Viral Interleukin-6: Role in Kaposi's Sarcoma-Associated Herpesvirus-Associated Malignancies
Shuhei Sakakibara et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2011)
KHSV- EBV- post-transplant effusion lymphoma with plasmablastic features: variant of primary effusion lymphoma?
Jennifer S. Lambe et al.
HEMATOLOGICAL ONCOLOGY (2009)
Profound inhibition of antigen-specific T-cell effector functions by dasatinib
Ralf Weichsel et al.
CLINICAL CANCER RESEARCH (2008)
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Andrew E. Schade et al.
BLOOD (2008)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
R Seggewiss et al.
BLOOD (2005)
Distinct cellular origins of primary effusion lymphoma with and without EBV infection
R Hamoudi et al.
LEUKEMIA RESEARCH (2004)
Regulation of growth signalling and cell cycle by Kaposi's sarcoma-associated herpesvirus genes
S Direkze et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2004)
Evidence for local immunosuppression and demonstration of c-myc amplification in pyothorax-associated lymphoma
H Yamato et al.
HISTOPATHOLOGY (2001)
The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells
SA Radkov et al.
NATURE MEDICINE (2000)
Share Paper
